Powerful Discovery and Development Engine
Achillion employs a highly-disciplined discovery and development approach that has enabled it to generate a portfolio of oral antivirals for chronic hepatitis C (HCV), including three clinical-stage candidates (an NS5A inhibitor, a protease inhibitor, and an NS5B nucleotide polymerase inhibitor), and a proprietary library of over 1,300 potent and specific complement factor D inhibitor compounds, as well as novel antibacterial compounds.
From early lead identification through clinical candidate selection, Achillion has coupled its knowledge base in genomic replication targets with an integrated drug discovery operation, powered by structure-guided design, to produce a prolific and sustainable discovery engine and facilitate the rapid advancement of its discovery programs.
Compound Synthesis, Hit Identification and Lead Optimization
Achillion’s anti-infective library of compounds contains a diverse set of molecules that have been synthesized for the principal purpose of inhibiting genomic replication in viruses and bacteria. Furthermore, Achillion’s complement inhibitor platform has generated a library of highly potent and specific inhibitors of the serine protease, factor D.
The Company has developed the following discovery tools that enable management of its compounds efficiently and advance its discovery programs. Explore:
Preclinical Candidate Selection
A cornerstone of Achillion’s approach to drug discovery and development is the early assessment of the drug-like properties associated with optimized lead compounds. Potency and activity against a given target are necessary but not sufficient predictors of eventual successful clinical development of a new drug. In order to perform an early assessment of the potential for successful development, prior to progression of a compound into late-stage preclinical studies in support of clinical trials, the Company aggressively evaluates compounds in numerous tests relating to safety, metabolism, pharmacokinetic properties and physical properties associated with the feasibility for an oral formulation.